Monica Holmberg, PharmD, BCPS

The FDA has approved orilissa (elagolix; AbbVie Inc) to manage moderate to severe pain asso- ciated with endometriosis.

The FDA has approved Ilumya (tildrakizum- ab-asmn) from Sun Pharmaceutical Industries Ltd to treat moderate to severe plaque psoriasis.

The FDA has approved olumiant to treat moderately to severely active rheumatoid arthritis.

Teva Pharmaceutical Industries Ltd has released Qvar Redihaler (beclomethasone dipropionate HFA).

The FDA has approved Lyrica CR (pregabalin, Pfizer) for the management of neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia.

The FDA has approved Duzallo (lesinurad and allopurinol; Ironwood Pharmaceuticals, Inc) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone.

The FDA has approved Tremfya (guselkumab, Janssen Biotech, Inc) for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The fda has approved mydayis (mixed salts of a single-entity amphetamine product, by Shire) to treat attention deficit hyperactivity disorder (ADHD) in patients 13 years or older.

The FDA has approved ingrezza capsules for the treatment of adults with tardive dyskinesia.

The FDA has approved Qtern tablets by AstraZeneca to improve glycemic control in adults with type 2 diabetes.

Both trials found that patients using Intrarosa demonstrated a significant reduction in the severity of pain during intercourse compared with the placebo.

The FDA has approved an expanded indication for Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in patients 6 years and older.

The FDA has approved an expanded indication for Tresiba to improve glycemic control in patients with diabetes as young as 1 year.

The FDA has approved Yosprala (aspirin and omeprazole, Aralez Pharmaceuticals) delayed-release tablets for patients requiring aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.

The FDA has approved Stelara injection for the treatment of adults with moderately to severely active Crohn’s disease who have failed, or were intolerant to, treatment with immunomodulators or corticosteroids.

Synjardy has received FDA approval for an expanded indication to include treatment-naïve adults with type 2 diabetes

​The FDA has approved byvalson (nebivolol and valsartan) tablets by Allergan for the treatment of hypertension (high blood pressure [BP]).

The FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate.

The FDA has approved Xtampza ER extended-release capsules, CII, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The FDA has approved Zembrace Symtouch subcutaneous injection for the acute treatment of migraine with or without aura in adult patients.

The FDA has approved bevespi aerosphere inhalation aerosol for the long-term maintenance treatment of airflow obstruction in patients with COPD.

The FDA has approved Basaglar, a long-acting human insulin analog, to improve glycemic control in adults and children with type 1 diabetes and in adults with type 2 diabetes.

The FDA has approved Quillichew ER extended-release chewable tablets for the treatment of ADHD in patients 6 years and older.

Dyanavel XR extended-release oral suspension has received FDA approval for the treatment of ADHD in patients 6 years and older.

The FDA has approved Vraylar, an atypical antipsychotic, for the treatment of schizophrenia and the acute treatment of mixed or manic episodes associated with bipolar I disorder.

The FDA has approved Utibron Neohaler oral inhalation powder for long-term maintenance treatment of airflow obstruction in patients with COPD.

The FDA has approved Belbuca buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.